Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWDDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $791.33M
- Beta
- 0.24
- P/E (TTM)
- 5.6
- EPS (TTM)
- $0.63
Volume 2.22M
Average 2.35M
IRWD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $21.5M fell 21.6% year over year, in line with the -21.9% change in trailing-twelve-month research & development. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at +29.1% a year.
Context
- Research & development amounted to 32.1% of revenue in FY2025, up 0.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -21.6% holds above the trailing-twelve-month pace of -21.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 95.14M USD
- Year-over-year change
- -14.6%
- 4-year CAGR
- +7.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.14M | -14.6% |
| FY2024 | 2024-12-31 | 111.42M | -4.0% |
| FY2023 | 2023-12-31 | 116.09M | +162.3% |
| FY2022 | 2022-12-31 | 44.27M | -37.1% |
| FY2021 | 2021-12-31 | 70.41M | — |
Research & Development vs competitors
How IRWD compares with its peers on the latest reported figures
- IRWD's LTM Mar 2026 research & development of $88.26M is the 2nd highest of the 3 companies compared; the peer median is $167.02M.
- Its year-over-year change of -21.9% is the lowest of 3, against a peer median of +40.1%.
- Research & development amounts to 24.4% of revenue for IRWD, versus a peer median of 152.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $259.72M | +46.3% | +43.1% | 287.0% | |
| LTM Mar 2026 | $88.26M | -21.9% | +29.1% | 24.4% | |
| LTM Mar 2026 | $74.32M | +33.9% | +24.8% | 17.4% | |
| Peer median (excluding IRWD) | $167.02M | +40.1% | +34.0% | 152.2% | |
Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 413.75M | 410.6M | 442.74M | 351.41M | 296.15M |
| Cost of Revenue | 70.41M | 1.42M | 6.15M | 7.55M | 0 |
| Gross Profit | 343.35M | 409.18M | 436.59M | 343.86M | 296.15M |
| Gross Margin | 83.0% | 99.7% | 98.6% | 97.9% | 100.0% |
| Research & Development | 70.41M | 44.27M | 116.09M | 111.42M | 95.14M |
| Selling, General & Admin | 0 | 115.99M | 0 | 0 | 82.26M |
| Operating Expenses | 111.09M | 158.84M | 1.38B | 250.73M | 177.39M |
| Depreciation & Amortization | 1.52M | 1.42M | 1.58M | 2.01M | 1.88M |
| EBITDA | 233.74M | 261.44M | 197.41M | 97.73M | 104.65M |
| EBITDA Margin | 56.5% | 63.7% | 44.6% | 27.8% | 35.3% |
| Operating Income | 232.26M | 250.34M | (945.43M) | 93.12M | 118.76M |
| Operating Margin | 56.1% | 61.0% | -213.5% | 26.5% | 40.1% |
| Interest Income | 726K | 9.5M | 18.97M | 4.47M | 4.08M |
| Interest Expense | 31.15M | 7.6M | 21.63M | 33.03M | 32.75M |
| Other Income / Expenses | (31.6M) | 2.09M | (2.64M) | (27.93M) | (48.73M) |
| Income Before Tax | 200.66M | 252.42M | (948.07M) | 65.2M | 70.03M |
| Pre-Tax Margin | 48.5% | 61.5% | -214.1% | 18.6% | 23.6% |
| Income Tax Expense | (327.79M) | 77.36M | 83.49M | 64.32M | 46.01M |
| Net Income | 528.45M | 175.07M | (1B) | 880K | 24.02M |
| Net Margin | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
| EPS (Basic) | 3.26 | 1.13 | (6.45) | 0.01 | 0.15 |
| EPS (Diluted) | 3.21 | 0.96 | (6.45) | 0.01 | 0.15 |
| Weighted Avg Shares | 162.25M | 154.37M | 155.44M | 159.08M | 162.22M |
| Weighted Avg Shares (Diluted) | 164.42M | 186.31M | 155.44M | 160.08M | 177.76M |
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
Intrinsic Alpha fair value
Locked
Current Price
$4.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.